Founded with the mission to expedite the availability of new treatments for the 350 million rare disease sufferers globally, Embleema is a healthcare blockchain provider. The company offers a data and bioinformatics platform designed to bring precision medicine to the next level. Their services include configuring studies through their Study Designer, recruiting participants online or in investigation centers, and securely sharing data collected by participants and investigators. Embleema's blockchain technology ensures participant consent with a full audit trail, while their proprietary HIVE platform generates evidence.
Notable affiliations include a partnership with CALYM to offer advanced clinical trial solutions for lymphoma R&D. Embleema's innovative approach has garnered attention from key investors and stakeholders in the healthcare and technology sectors. The company's achievements in enhancing clinical trial efficiency and data security have made a significant impact on the acceleration of treatment availability for rare diseases, positioning Embleema as a leader in healthcare blockchain technology.
Quick Facts
How much disclosed funding has Embleema raised?
As of Dec 17, 2019, Embleema has disclosed funding of $3.7M (USD).